Pharmacist | New Grad/Resident | Technician | Intern/Student | |
Member | $160 | $80 | $80 | $25 |
Non-Member | $240 | $160 | $160 | $80 |
Date: Oct 11, 2024 08:00 AM - 05:00 PM
CE Hours
CE Units
Activity Type
- Knowledge-Based and Application-Based
Target Audience(s)
- Pharmacists
- Pharmacy Technicians
Accreditation(s)
The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Co-Sponsor(s)
Requirements for CE Credit
- Analyze the current landscape of pharmacy school admissions and the factors influencing applicant availability and selection
- Identify key changes in pharmacy education resulting from the approval of ACPE “Standards 2025” for the Doctor of Pharmacy program
- Differentiate the essential skill sets and characteristics of pharmacy school graduates that facilitate successful integration into the healthcare workforce
Speaker(s)/Author(s)
Giuseppe Gumina, PhD
|
|
Julie Sease, PharmD, FCCP, BCPS, CDCES, BCACP
|
|
Phillip Hall, PharmD
|
Activity Number
0062-9999-24-177-L99-P/TCE Hours
- Discuss the 2024 guideline updates for DKA and HHS
- Identify opportunities to update practices matching new guideline updates
- Identify opportunities within transitions of care to prevent re-admissions in patients receiving insulin
- Recognize differences between short-acting and long-acting insulin products
Speaker(s)/Author(s)
Abbygail Wilbourn, PharmD, MSPS
|
Activity Number
0062-9999-24-178-L01-P/TCE Hours
- Describe the pathophysiology of vasodilatory shock
- Discuss angiotensin II, methylene blue, and hydroxocobalamin usage in vasodilatory shock using primary literature
- Describe the pathophysiology of vasodilatory shock
- Describe sterile preparation of angiotensin II, methylene blue, and hydroxocobalamin
Speaker(s)/Author(s)
Abigail Rath, PharmD
|
Activity Number
0062-9999-24-179-L01-P/TCE Hours
- Recall key peer review evidence impacting obesity management
- Identify expanded indications and newly approved anti-obesity medications
- Summarize important updates in obesity-related clinical practice guidelines
Speaker(s)/Author(s)
Reagan Barfield, PharmD, BCPS
|
Activity Number
0062-9999-24-180-L01-P/TCE Hours
- Analyze the appropriateness of the addition of gene therapies to a health-system's formulary
- Assemble the necessary team members from throughout a health system to implement best practices for Gene Therapy implementations
- Describe best practices for the handling of Gene Therapies in the preparation of products for patient administration
- Analyze the appropriateness of the addition of gene therapies to a health-system's formulary
- Identify appropriate storage and handling of Gene Therapies and the importance of monitoring and security systems
- Describe best practices for the handling of Gene Therapies in the preparation of products for patient administration
Speaker(s)/Author(s)
Corey Jennings, MBA, CHFP
|
|
Eric Chmielewski, PharmD, MS, BCOP
|
|
Harrison Jozefczyk, PharmD, MS
|
Activity Number
0062-9999-24-181-L01-P/TCE Hours
- Describe pharmacist impact on commonly encountered clinical scenarios
- Provide an example of appropriate continuity of care for commonly encountered clinical scenarios
- Recognize medication safety principles in commonly encountered clinical scenarios
- Describe the importance of utilizing evidence-based medicine in commonly encountered clinical scenarios
Activity Number
0062-9999-24-182-L01-P/TCE Hours
- Discuss the importance of correct PPE use when handling hazardous substances in the pharmacy
- Interpret current studies that highlight hazardous risks to healthcare workers
- Analyze the effectiveness of PPE in hazardous sterile compounding
- Identify the improvements made to healthcare worker safety with the publishing of USP chapters <797> and <800>
Speaker(s)/Author(s)
Giuliana Lyke, PharmD, BCSCP, DPLA
|
|
Savannah Mancuso-Noyes, PharmD, BCSCP
|
Activity Number
0062-9999-24-183-L05-P/TCE Hours
- Recall the pathophysiology of endometriosis and associated complications
- Differentiate pharmaceutical agents utilized for the management of endometriosis-associated pain
- Assess various clinical trials used in the selection of the pharmaceutical agents for endometriosis-associated pain
- Recall the pathophysiology of endometriosis and associated complications
- Identify pharmaceutical agents utilized for the management of endometriosis-associated pain
- Relate adverse effects of medications used to treat endometriosis with incidence reported in clinical trials
Speaker(s)/Author(s)
Jacob Krissinger, PharmD Candidate 2025
|
|
Julia Geith, PharmD Candidate 2025
|